We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Over the next two years, drugmakers will have to finesse the way they handle price breaks for large-volume purchasers in order to have those prices excluded from future reimbursement averages determined by legislators under the new Medicare Rx drug law.
The attorney general of Arkansas has sued generic firms Dey and Warrick Pharmaceuticals, as well as Warrick’s affiliates Schering-Plough and Schering, for misreporting their average wholesale prices (AWPs), allegedly fraudulently inflating Medicaid and Medicare reimbursement rates to physicians and other providers.
The way drugmakers handle demands for price breaks from large-volume purchasers over the next two years will help determine whether those price concessions will be taken into account when setting reimbursement formulas under the new Medicare Rx law.
As HHS implements the new Medicare reimbursement system for many physician-administered outpatient drugs, pharma firms are likely to find themselves confronted by many of the same fraud and abuse issues they have had to deal with under the much-criticized average wholesale price (AWP) system — as well as some new issues — according to a healthcare legal expert.
Senate staffers hope to have sorted through the details of a pair of proposed amendments to the recently passed Medicare Rx law prior to Congress’ return from recess Jan. 20 to distill a final form for a Democratic caucus bill later this year, congressional staffers told WDL Jan 12.
Senate staffers are expected to sort through the details of a pair of proposed amendments to the recently passed Medicare Rx law to decide what to put into a Democratic caucus bill being prepared for Congress’ return from recess Jan. 20, congressional staffers told DID yesterday.
With the reimbursement rates for Medicare-covered drugs having changed at the beginning of the year in response to the Medicare prescription drug benefit law, drugmakers
Drugmakers could face new marketing challenges as Medicare reduces reimbursement rates for certain outpatient drugs, cutting price spreads that created incentives for doctors to prescribe more expensive drugs.
HHS Secretary Tommy Thompson should use the department’s federal negotiating power to lower the costs of drugs under Medicare, according to a bipartisan group of 16 senators.